CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone

Original Research16 Sep 2019

JOURNAL:Circulation. Article Link

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif ME, Windsor S, DEFINE-HF Investigators. Keywords: SGLT-2 inhibitors; HFrEF; T2DM; Dapagliflozin effect

FULL TEXT PDF